Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results

By Chris Lange Updated Jan 12, 12:01PM EST · Published May 15, 10:30AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results — © Thinkstock

[cnxvideo id=”510061″ placement=”ros”]Ionis Pharmaceuticals Inc. (NASDAQ: IONS) saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy. Although the results from this Phase 3 trial of inotersen met its primary endpoints, there was still some data that held the stock back.

Unfortunately, adverse effects considered to be related to treatment were seen more commonly with inotersen than in the placebo. Two key safety findings were observed during the study that required changes to the monitoring schedule. Three serious adverse events of thrombocytopenia were observed in inotersen-treated patients. Two patients recovered and one patient died due to intracranial hemorrhage.

One additional inotersen-treated patient discontinued treatment due to non-serious thrombocytopenia. Four inotersen-treated patients discontinued treatment due to a renal observation. Two patients met a predefined renal stopping rule, and two experienced serious renal adverse events, one of whom experienced chronic renal insufficiency.

[nativounit]

All five serious adverse events — including one placebo related event — occurred before enhanced monitoring was fully implemented.

Morie Gertz, M.D., MACP, Division of Hematology, and Roland Seidler Jr., Professor Department of Medicine, College of Medicine, Mayo Distinguished Clinician, commented:

Familial amyloid polyneuropathy is a devastating genetic disease that is painful and rapidly progressive leading to early death. The positive results from the NEURO-TTR study today are very encouraging for this underserved patient population. I have been treating patients with this disabling disease for many years, and I am excited about the promise that inotersen holds to restore their lives. I believe inotersen has the potential to transform the current standard of care for patients with TTR amyloidosis.

Shares of Ionis traded down 9% at $42.84 early Monday, with a consensus analyst price target of $45.36 and a 52-week trading range of $19.59 to $57.00.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.